April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Pressure Lowering Effect of ONO-9054: a novel FP/EP3 dual agonist
Author Affiliations & Notes
  • Alon Harris
    Ophthalmology, Indiana University, Indianapolis, IN
  • Cheryl L Rowe-Rendleman
    Ono Pharma, Trenton, NJ
  • Douglas T Ross
    Ono Pharma, Trenton, NJ
  • Akifumi Fujii
    Ono Pharma, Trenton, NJ
  • Takafumi Ouchi
    Ono Pharma, Trenton, NJ
  • Andrew Wood
    Ono Pharma, Trenton, NJ
  • Footnotes
    Commercial Relationships Alon Harris, Adom (I), Alcon (R), Biolight (C), Merck (C), MSD (R), Nano Retina (C), ONO Pharmaceuticals (C), Pharmalight (C), Sucampo (C); Cheryl Rowe-Rendleman, ONO Pharma (C); Douglas Ross, ONO Pharma (E); Akifumi Fujii, ONO Pharma (E); Takafumi Ouchi, ONO Pharma (E); Andrew Wood, ONO Pharma (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 560. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alon Harris, Cheryl L Rowe-Rendleman, Douglas T Ross, Akifumi Fujii, Takafumi Ouchi, Andrew Wood; Pressure Lowering Effect of ONO-9054: a novel FP/EP3 dual agonist. Invest. Ophthalmol. Vis. Sci. 2014;55(13):560.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Almost 20% of patients on prostaglandin analogues (PGA) monotherapy eventually require some form of adjunctive drug therapy to sufficiently sustain low IOP. In the present study the pressure lowering effect of 4 concentrations of ONO-9054 a dual FP/EP3 agonist was examined in order to measure the proportion that sustained a target of IOP of <18 mmHg.


48 subjects with ocular hypertension (OHT) or early primary opem angle glaucoma (OAG) were washed out of all IOP lowering drugs. Those with IOP >22 mmHg at 8:00am and >21 mmHg at 10am at the eligibility visits were randomized 1:3 to placebo or one of 4 active doses of ONO-9054 at 3, 10, 20 or 30 ug/mL. Study drug was administered once a day at 7am for 14 days. The timing of IOP measures after 14 days of dosing was paired to occur at approximately the same time as the predose baseline measurements.


The percentage of patients reaching specific target pressures after 14 days dosing was determined.


In our analysis all subjects on ONO-9054 experienced a reduction in IOP to 18 mmHg or less after 14 days dosing. At higher doses of the drug, IOPs of 16 mmHg or less were more frequent.

Keywords: 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • 568 intraocular pressure • 583 lipids  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.